XML 72 R41.htm IDEA: XBRL DOCUMENT v3.25.4
SEGMENT REPORTING (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table presents segment revenue and significant segment expenses (in thousands) for the years ended December 31, 2025 and 2024:
YEAR ENDED DECEMBER 31,
20252024
REVENUE:
Total segment revenue$244,061 $3,550 
LESS:
Rinvatercept program expenses(7,081)(16,090)
Elritercept program expenses(38,030)(44,319)
Cibotercept program expenses(12,562)(29,777)
Preclinical & development expenses(6,847)(12,008)
Compensation costs (excluding stock based compensation)(45,331)(48,084)
Other external costs(35,095)(26,708)
Other segment items3(12,101)(13,917)
Net income (loss)$87,014 $(187,353)